Pembrolizumab - Uses, How It Works & Side Effects

What Is Pembrolizumab?

As understanding of cancer and the immune system grew, scientists began developing new medicines that help the body defend itself against cancer. Pembrolizumab, a drug created as part of this new method, is routinely used to treat various types of cancer. It includes lung cancer and skin cancer. It works by increasing the immune system's ability to recognize and fight cancer cells. Pembrolizumab is a prescription drug and should only be given under the care of a trained cancer specialist. Patients should tell their healthcare team right away if they notice any new symptoms or if existing symptoms get worse.

Is Pembrolizumab FDA-Approved?

• The U.S. Food and Drug Administration (FDA) has approved Pembrolizumab for use in numerous cancer treatments.

• Pembrolizumab was first approved in 2014. It was used to treat patients with advanced melanoma that could not be removed by surgery or had spread to other parts of the body, especially when the cancer had continued to grow despite treatment with Ipilimumab.

• In 2016, the FDA approved it for specific forms of lung cancer.

• Since then, its application has spread to a variety of tumors, including gastric cancer, head and neck cancer, colorectal cancer, and others.

• The FDA continues to approve new indications, indicating that the drug is now approved in the United States for a wide range of cancer types and clinical conditions.

How Pembrolizumab Works?

• The immune system employs specialized cells to detect and kill dangerous cells in the body.

• Cancer cells can protect themselves by inhibiting these immune cells.

• They accomplish this by inhibiting the immune system via a protein known as PD-1 (programmed cell death-1).

• PD-1 is a protein found on T cells that acts as a safety switch. It helps stop the immune system from attacking normal, healthy cells. Cancer cells exploit this system by producing a protein called PD-L1.

• When PD-L1 binds to PD-1, it sends a signal that causes the immune system to ignore the cancer.

• Pembrolizumab works by blocking this interaction between PD-1 and PD-L1.

• Blocking the interaction between PD-1 and PD-L1 removes the brake on immune cells. This restores immune cell activity.

• The T-cells become active, recognize the cancer as a threat, and can go after and destroy cancer cells more effectively. Active immune cells are better able to spot and fight cancer cells.

• This helps to halt or control the progression of cancer.

Indications - Cancer Types Treated

• Pembrolizumab is used to treat lung cancer, especially in its advanced or metastatic stages.

• It is used to treat melanoma and to help stop the spread of skin cancer.

• Pembrolizumab is prescribed for bladder cancer to decrease disease progression.

• It is also utilized in kidney cancer treatment as part of an immune therapy regimen.

• Pembrolizumab can treat colorectal tumors that have certain genetic markers.

• In certain patients, the medication is licensed to treat stomach and esophageal malignancies.

• It is also used to treat cervical cancer and select forms of breast cancer.

• The medicine is also used to help with immune-based tumor control in head and neck malignancies (usually in squamous cell carcinoma of the head and neck).

Dosage & Administration

1. For Adult Cancer Treatment:

• Pembrolizumab is administered intravenously at a hospital or clinic.

• A typical dosage is 200 mg administered once every three weeks.

• Another permitted option is 400 mg administered once every six weeks.

• Each infusion normally takes around 30 minutes to complete.

• Treatment continues as long as the patient benefits and the side effects are tolerable.

2. For Pediatric or Weight-Based Use (In Some Cancers):

• The dosage can be estimated based on body weight.

• In such circumstances, it is typically administered by IV infusion every 3 weeks.

• Doctors carefully alter dosing and continuously monitor the youngster throughout treatment.

3. General Administration:

• Pembrolizumab should be administered only by trained healthcare professionals.

• Patients are monitored throughout and after the infusion for potential responses.

• If substantial adverse effects occur, treatment may be temporarily slowed or discontinued.

What Are the Side Effects?

Pembrolizumab activates the immune system, which can result in side effects.

1. Side Effects That Are Frequently Encountered Include:

• Fatigue.

• Fever or flu-like symptoms.

• Itching or a skin irritation.

• Appetite reduction or nausea.

2. Side Effects Associated With the Immune System:

• Pneumonitis is an inflammation of the airways that results in coughing or shortness of breath.

• Yellowing of the epidermis or eyes is a consequence of liver inflammation.

• Diarrhea or abdominal discomfort as a result of intestinal inflammation.

• Thyroid, adrenal, or pituitary gland dysfunction.

3. Effects That Are Less Prevalent but More Severe:

• Allergic reactions that are severe during the infusion process

• The kidneys, heart, or other organs are the targets of an immune system attack.

• Doctors may modify or suspend treatment in the event of severe adverse effects, and patients are closely monitored.

4. Pembrolizumab May Have Serious Side Effects on the Following Body Parts and Organs:

• Lung disease (pneumonitis) can make you cough and have trouble breathing.

• Inflammation of the liver (hepatitis) can make the skin or eyes turn yellow.

• Inflammation of the intestines, also known as colitis, can cause severe diarrhea and stomach pain.

• Problems with hormone glands, like the thyroid or adrenal glands, can make you tired or cause your weight to change.

• Kidney inflammation can lead to less urine production or swelling.

Who Shouldn’t Take Pembrolizumab?

Not everyone is a good candidate for Pembrolizumab.

It is recommended that the following people avoid using it:

• Individuals who have had serious adverse responses to Pembrolizumab or any of its components.

• Patients with active autoimmune disorders (such as multiple sclerosis or lupus) may notice a worsening of their condition during immune system activation.

• People who have had organ transplants, such as Pembrolizumab, may cause the body to reject the transplanted organ.

• Pregnant women should avoid such activities unless the potential benefits outweigh the risks, as they may damage their unborn child.

• Breastfeeding mothers, as it is unknown whether the chemical passes into breast milk.

• Patients with uncontrolled infections, as the immune system activity may worsen the infection.

• Physicians do a detailed review of the patient's medical history and current health before prescribing Pembrolizumab to ensure its safety.

Conclusion

Pembrolizumab is a new cancer medication that boosts the body's immune system to fight cancer. This treatment is carefully planned and closely monitored by an oncologist to ensure it is right for the patient. Patients often need to go to the hospital so doctors can monitor their progress and spot adverse effects early.

Talking clearly with the cancer specialist helps solve difficulties quickly and leads to better treatment outcomes.